Cargando…
Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches
The treatment landscape of classical Hodgkin lymphoma (cHL) has undergone significant changes over the past 20 years. Gradual improvements have been made in the management of cHL patients, particularly in prolonging the survival rate for those in the relapsed setting. Most of these improvements came...
Autores principales: | Hanel, Walter, Herrera, Alex F., Epperla, Narendranath |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793517/ https://www.ncbi.nlm.nih.gov/pubmed/36575540 http://dx.doi.org/10.1186/s40164-022-00360-4 |
Ejemplares similares
-
Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies
por: Hanel, Walter, et al.
Publicado: (2021) -
Emerging therapies in mantle cell lymphoma
por: Hanel, Walter, et al.
Publicado: (2020) -
A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma
por: Hanel, Walter, et al.
Publicado: (2023) -
Current directions in the treatment of classical Hodgkin lymphoma
por: Keller, Frank G., et al.
Publicado: (2023) -
Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib
por: Denlinger, Nathan M, et al.
Publicado: (2018)